The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …

T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in
individuals with hematological malignancies, but its success has been hindered by barriers …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling
pathways in tumor cells help produce a suppressive tumor microenvironment enriched for …

Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the “next
generation” of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the …